Apogee Therapeutics Reports Q3 2024 Financial Results and Pipeline Progress

Apogee Therapeutics, Inc.

2024-Q3 EPS reported -$2.11

Cash, cash equivalents and marketable securities of $753.8M as of Sept 30, 2024, with runway into 2028.
Net loss for Q3 2024 was $49.0M, compared to $20.8M in Q3 2023.
APG777 Phase 2 Part A data expected in 2H 2025; interim Phase 1 data for APG808 in 4Q 2024.
APG333 development candidate nominated; Phase 1 planned for late 2024 or early 2025.
Jeff S. Hartness appointed as Chief Commercial Officer in September 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.